505 Clinical evidence of intra-tumoral immune activation and tumor targeting with RG, a CEA-targeted engineered IL-2 immunocytokine. (September 2015) - Tabernero, J.; Homicsko, K.; Schellens, J.H.; Hoekstra, O.; Van der Veen, L.; Melero, I.; és, G. Argil; Mau-Sorensen, M.; Angevin, E.; Joensuu, H.; Van Brummelen, E.; van Oordt, C.W. Menke-van der Houven; et al.